Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | Retrospective analysis of lenalidomide and thalidomide in myelofibrosis

Andrew Kuykendall • 25 Aug 2020
Myelofibrosis Myeloproliferative Neoplasms Lenalidomide Thalidomide

Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, explores results from a retrospective analysis of the clinical use and benefit of lenalidomide and thalidomide in myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrew Kuykendall

Practice-changing findings in MPNs from ASCO 2025 0:57
Practice-changing findings in MPNs from ASCO 2025
Andrew Kuykendall • 1 Jun 2025
The IMproveMF study: combining imetelstat with ruxolitinib for the treatment of myelofibrosis 0:58
The IMproveMF study: combining imetelstat with ruxolitinib for the treatment of myelofibrosis
Andrew Kuykendall • 1 Jun 2025
An overview of novel JAKis in myelofibrosis: which patients benefit from pacritinib & momelotinib? 1:31
An overview of novel JAKis in myelofibrosis: which patients benefit from pacritinib & momelotinib?
Andrew Kuykendall • 1 Jun 2025
Results from the VERIFY trial: the encouraging efficacy of rusfertide in patients with PV 2:32
Results from the VERIFY trial: the encouraging efficacy of rusfertide in patients with PV
Andrew Kuykendall • 1 Jun 2025

Related Videos

12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET 2:25
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
Jean-Jacques Kiladjian • 8 Dec 2025
Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera 2:04
Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera
Aniket Bankar • 8 Dec 2025
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms 1:39
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms
Roman Doll • 7 Dec 2025
Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals